Vitamin B7 and Biotin: A Metabolic Escape Route for Cancer Tumours

Across cancer laboratories in Europe, an unassuming vitamin more commonly associated with hair supplements is unexpectedly drawing attention away from blockbuster medicines.

Scientists increasingly believe that vitamin B7, also called biotin, could be one of the subtle mechanisms that enables tumours to survive after their preferred fuel source has been removed.

How a humble vitamin gives tumours a metabolic escape route

New research from the University of Lausanne reveals an unexpected part played by vitamin B7 in how cancer cells meet their energy demands.

Cancer cells frequently have a pronounced “addiction” to glutamine, an amino acid that supplies both carbon and nitrogen. They depend on it to support energy generation and to make DNA and other essential compounds. Numerous experimental medicines aim to deprive tumours by interrupting this glutamine supply.

However, certain tumours continue to grow despite limited glutamine. The Swiss researchers have now demonstrated that vitamin B7 may account for how they achieve this striking ability.

Vitamin B7 acts like a metabolic licence, allowing cancer cells to bypass their dependence on glutamine and switch to a backup fuel.

At the heart of the process is an enzyme known as pyruvate carboxylase. Enzymes are proteins that accelerate chemical reactions within cells. Pyruvate carboxylase changes pyruvate, a product created when glucose is broken down, into oxaloacetate.

Oxaloacetate subsequently enters the Krebs cycle, the chain of mitochondrial reactions responsible for producing much of a cell’s energy. When glutamine supplies decline, some cancer cells direct additional pyruvate through this pathway to maintain the Krebs cycle. This replenishment mechanism is called anaplerosis.

Vitamin B7 is essential to this process. For pyruvate carboxylase to function correctly, biotin must attach directly to it. In the absence of this attachment, the reaction stops, the Krebs cycle cannot be refilled, and the cell is unable to make up for missing glutamine. Its growth then slows sharply.

Why some anti-glutamine therapies fail

Through detailed metabolic tracing and broad genetic screening, the Lausanne team found that biotin and pyruvate carboxylase are central to this escape route.

These results help clarify why treatments aimed only at glutamine metabolism have produced underwhelming trial results. A tumour with an effective biotin–pyruvate carboxylase system can instead redirect glucose-derived fuel.

Blocking glutamine alone may be like closing one door while leaving a side entrance wide open.

Future treatment approaches may therefore need to target both the glutamine pathway and this biotin-dependent fallback route simultaneously, at least for tumours that depend upon it.

When genetics turn a strength into a weakness: the FBXW7 link

The findings extend beyond nutrients. The same research identifies a strong relationship between vitamin B7 and FBXW7, a gene recognised as a tumour suppressor.

In normal circumstances, FBXW7 tightly controls c-MYC, a potent protein that promotes growth. By helping to remove c-MYC from cells, FBXW7 limits excessive cell division.

This control breaks down when FBXW7 is mutated. c-MYC then accumulates and alters the activity of numerous metabolic genes. A notable consequence is reduced pyruvate carboxylase production.

When pyruvate carboxylase levels are lower, cancer cells lose much of their capacity to use pyruvate as an alternative fuel when glutamine is scarce. They become heavily reliant once more on glutamine to continue dividing.

The same genetic mutation that drives cancer growth can also strip away its metabolic backup plan, creating a hidden vulnerability.

This illustrates that tumour resistance is shaped by more than the nutrients in a tumour’s environment. It also reflects the particular genetic setting of each tumour. Some mutations directly alter which fuels a tumour can, or cannot, survive without.

Metabolic flexibility: a defining trait of cancer cells

Vitamin B7 draws attention to a wider principle in cancer biology: metabolic flexibility. The phrase describes cells’ capacity to change energy sources according to what is available.

As glutamine concentrations drop, some tumours avert a crisis by increasing their use of pyruvate through the biotin-dependent pyruvate carboxylase pathway. Others can draw on fatty acids or alternative amino acids.

This adaptability helps explain why metabolic drugs with a single target often reach a limit. Shutting down one pathway merely prompts cancer cells to rely more on another.

• Drugs focused on glutamine may be ineffective when pyruvate carboxylase is active.
• Medicines targeting glucose may be avoided through increased reliance on glutamine or fats.
• Genetic mutations determine which fallback pathways are genuinely accessible.

Developing future treatments will probably require combinations that target several pathways, tailored to the metabolic and genetic profile of each tumour.

Could vitamin B7 itself become a therapeutic target?

Biotin is typically regarded as a harmless micronutrient. It is common in foods and supplements, and it contributes to normal metabolism, including that of healthy cells.

The new evidence does not mean patients should avoid biotin or alter their diets. The concentrations studied, and the way tumour microenvironments process vitamin B7, are different from ordinary nutrition.

Researchers instead see potential in identifying tumours that depend particularly strongly on biotin-dependent enzymes. In these cancers, medicines that disrupt biotin use, or particular biotin-requiring enzymes such as pyruvate carboxylase, might improve the effectiveness of glutamine-targeting treatments.

Biotin is shifting from background micronutrient to a potential handle for precision oncology.

These methods present genuine difficulties. Many tissues need biotin, meaning that systemic blockade might cause adverse effects ranging from nerve problems to skin conditions. An important question is whether drugs can be created to work chiefly in cancer cells, perhaps by taking advantage of differences in enzyme abundance or nutrient transporters.

What patients and clinicians might want to know

For people with cancer, these findings are not a reason either to start buying biotin supplements or to stop using them. This research relies on cell models and complex metabolic mapping rather than clinical trials examining vitamin consumption.

The importance of this work lies in the longer-term development of treatment combinations. One day, oncologists may request tests that assess not only conventional mutations but also enzymes such as pyruvate carboxylase and indicators of biotin use. This may help classify tumours into groups including:

Key terms that often confuse readers

Two ideas occur frequently in this area of research and merit explanation.

Anaplerosis describes reactions that replenish the Krebs cycle with fresh carbon molecules, allowing it to continue operating. Without anaplerosis, the cycle ultimately lacks raw material and its energy production falls.

Tumour suppressor genes, including FBXW7, function as brakes on cell survival or division. If they are damaged, cells may divide more freely and often alter how they use nutrients. This can both support cancer growth and produce vulnerabilities that targeted medicines could exploit.

As scientists continue charting these connected pathways, vitamin B7 is likely to appear more regularly in conversations about cancer-not as a lifestyle trend, but as a small molecule positioned at a surprisingly important intersection of tumour metabolism and resistance.